דקסטרוז % 4.3 ו-% 0.18 סודיום כלוריד ויוסר תמיסה לעירוי
eldan electronic instruments co ltd, israel - dextrose anhydrous; sodium chloride - תמיסה לאינפוזיה - dextrose anhydrous 4.3 %w/v; sodium chloride 0.18 %w/v - sodium chloride
מניטולויוסר תמיסה לעירוי 20%
eldan electronic instruments co ltd, israel - mannitol - תמיסה לאינפוזיה - mannitol 200 mg/ml - mannitol
diathermy system+accessories
מדי פישר הנדסה ומדע (2002) בע"מ - רופא - מערכות דיאטרמיה + נלווים
stimulation & biofeedback
חגי מכשור רפואי וסיעודי בע"מ - מומחה - המכשיר מיועד לאבחון תנועות שרירים רצוניים ובלתי רצוניים ושיקומם ע'י סטימולטור
אקסג'יבה
amgen europe b.v. - denosumab - תמיסה להזרקה - denosumab 120 mg / 1.7 ml - denosumab - denosumab - prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.
פרוליה 60 מג
amgen europe b.v. - denosumab - תמיסה להזרקה - denosumab 60 mg / 1 ml - denosumab - denosumab - treatment of osteoporosis in postmenopausal women at incresed risk of fractures. prolia significantly reduces the risk of vertebral, non vertebral and hip fractures.treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. in men with prostate cancer receiving hormone ablation, prolia significantly reduces the risk of vertebral fractures.
אוויסטה
eli lilly israel ltd, israel - raloxifene hydrochloride - טבליות מצופות פילם - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - evista is indicated for the treatment of osteoporosis in post menopausal women. evista is indicated for the prevention of osteoporosis in post menopausal women . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.
ראלוקסיפן טבע
teva israel ltd - raloxifene hydrochloride - טבליה - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - - treatment of osteoporosis in post menopausal women. - prevention of osteoporosis in post menopausal women .
ראלוקסיפן טבע
teva israel ltd - raloxifene hydrochloride - טבליה - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - - treatment of osteoporosis in post menopausal women. - prevention of osteoporosis in post menopausal women .
ריזדרונט טבע 35 מג
abic marketing ltd, israel - risedronic acid as sodium - טבליה - risedronic acid as sodium 35 mg - risedronic acid - risedronic acid - treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. treatment of osteoporosis in men at high risk of fracture.